MX2021009274A - Moleculas de union a multiples dominios. - Google Patents
Moleculas de union a multiples dominios.Info
- Publication number
- MX2021009274A MX2021009274A MX2021009274A MX2021009274A MX2021009274A MX 2021009274 A MX2021009274 A MX 2021009274A MX 2021009274 A MX2021009274 A MX 2021009274A MX 2021009274 A MX2021009274 A MX 2021009274A MX 2021009274 A MX2021009274 A MX 2021009274A
- Authority
- MX
- Mexico
- Prior art keywords
- binding
- immtac
- hla
- restricted peptide
- life extended
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a moléculas solubles de unión a múltiples dominios que comprenden receptores de células T (TCR) que tienen especificidad para un antígeno, un dominio Fc de inmunoglobulina o una fracción de unión a albúmina; y un dominio efector inmunitario. Tales moléculas de unión a múltiples dominios son ventajosas debido a que muestran una vida media mejorada mientras retienen la función.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1901306.9A GB201901306D0 (en) | 2019-01-30 | 2019-01-30 | Multi-domain binding molecules |
PCT/EP2020/052316 WO2020157211A1 (en) | 2019-01-30 | 2020-01-30 | Half-life extended immtac binding cd3 and a hla-a*02 restricted peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021009274A true MX2021009274A (es) | 2021-08-24 |
Family
ID=65997844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021009274A MX2021009274A (es) | 2019-01-30 | 2020-01-30 | Moleculas de union a multiples dominios. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220119479A1 (es) |
EP (1) | EP3917955A1 (es) |
JP (1) | JP2022523722A (es) |
KR (1) | KR20210121120A (es) |
CN (1) | CN113474367A (es) |
AU (1) | AU2020213907A1 (es) |
BR (1) | BR112021014962A2 (es) |
CA (1) | CA3126628A1 (es) |
GB (1) | GB201901306D0 (es) |
IL (1) | IL284891A (es) |
MX (1) | MX2021009274A (es) |
WO (1) | WO2020157211A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
WO2022184805A1 (en) | 2021-03-03 | 2022-09-09 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein |
KR20230169944A (ko) | 2021-03-09 | 2023-12-18 | 씨디알-라이프 아게 | Mage-a4 펩티드-mhc 항원 결합 단백질 |
EP4198052A1 (en) | 2021-12-15 | 2023-06-21 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers |
WO2023156663A1 (en) | 2022-02-20 | 2023-08-24 | Immunocore Limited | Hiv-specific binding molecules and tcr |
WO2024038183A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
US20240092859A1 (en) * | 2022-08-18 | 2024-03-21 | Immunocore Ltd | T cell receptors and fusion proteins thereof |
WO2024038193A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024038198A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6685698A (en) | 1997-03-07 | 1998-09-22 | Sunol Molecular Corporation | Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor |
JP2001519143A (ja) | 1997-10-02 | 2001-10-23 | スノル・モレキュラー・コーポレーション | 可溶性の一本鎖t細胞レセプタータンパク質 |
WO2001062908A2 (en) | 2000-02-22 | 2001-08-30 | Ahuva Nissim | Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof |
ATE290020T1 (de) | 2001-08-31 | 2005-03-15 | Avidex Ltd | Löslicher t zell rezeptor |
US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
GB0227351D0 (en) * | 2002-11-22 | 2002-12-31 | Isis Innovation | Soluble T-cell receptors |
DK1791865T3 (da) | 2004-06-29 | 2010-11-01 | Immunocore Ltd | Celler der udtrykker en modificeret T-cellerecptor |
EP2365000A3 (en) | 2005-05-18 | 2013-01-16 | Ablynx N.V. | Improved nanobodiesTM against tumor necrosis factor-alpha |
US8512873B2 (en) | 2008-07-22 | 2013-08-20 | Furukawa Electric Co., Ltd. | Surface treated copper foil and copper clad laminate |
GB0908613D0 (en) * | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
WO2013041865A1 (en) | 2011-09-22 | 2013-03-28 | Immunocore Limited | T cell receptors |
GB201522592D0 (en) | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
CR20180531A (es) | 2016-04-08 | 2019-06-13 | Immunocore Ltd | Receptores de células t |
JP2019517499A (ja) * | 2016-06-02 | 2019-06-24 | イムノコア リミテッド | gp100特異的TCR−抗CD3 scFv融合タンパク質の投薬レジメン |
WO2018132597A1 (en) * | 2017-01-12 | 2018-07-19 | Eureka Therapeutics, Inc. | Constructs targeting histone h3 peptide/mhc complexes and uses thereof |
GB201709866D0 (en) | 2017-06-20 | 2017-08-02 | Immunocore Ltd | T cell receptors |
BR112020023195A2 (pt) * | 2018-05-14 | 2021-09-28 | Immunocore Limited | Polipeptídeos de ligação bifuncional, composição farmacêutica, ácido nucleico, vetor de expressão, célula hospedeira, método para preparar o polipeptídeo de ligação bifuncional, e método para tratar um distúrbio autoimune |
-
2019
- 2019-01-30 GB GBGB1901306.9A patent/GB201901306D0/en not_active Ceased
-
2020
- 2020-01-30 KR KR1020217026912A patent/KR20210121120A/ko unknown
- 2020-01-30 AU AU2020213907A patent/AU2020213907A1/en active Pending
- 2020-01-30 CN CN202080012052.4A patent/CN113474367A/zh active Pending
- 2020-01-30 JP JP2021544405A patent/JP2022523722A/ja active Pending
- 2020-01-30 MX MX2021009274A patent/MX2021009274A/es unknown
- 2020-01-30 WO PCT/EP2020/052316 patent/WO2020157211A1/en unknown
- 2020-01-30 EP EP20703193.1A patent/EP3917955A1/en active Pending
- 2020-01-30 US US17/427,581 patent/US20220119479A1/en active Pending
- 2020-01-30 CA CA3126628A patent/CA3126628A1/en active Pending
- 2020-01-30 BR BR112021014962-7A patent/BR112021014962A2/pt unknown
-
2021
- 2021-07-15 IL IL284891A patent/IL284891A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20220119479A1 (en) | 2022-04-21 |
WO2020157211A1 (en) | 2020-08-06 |
AU2020213907A1 (en) | 2021-09-09 |
CN113474367A (zh) | 2021-10-01 |
KR20210121120A (ko) | 2021-10-07 |
IL284891A (en) | 2021-08-31 |
CA3126628A1 (en) | 2020-08-06 |
GB201901306D0 (en) | 2019-03-20 |
EP3917955A1 (en) | 2021-12-08 |
BR112021014962A2 (pt) | 2021-09-28 |
JP2022523722A (ja) | 2022-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021009274A (es) | Moleculas de union a multiples dominios. | |
PH12021550662A1 (en) | Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously | |
Cai et al. | Synthetic multivalent glycopeptide‐lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells | |
CY1124664T1 (el) | Υποδοχεις τ λεμφοκυτταρων | |
CY1121558T1 (el) | Διλειτουργικα πολυπεπτιδια | |
CY1124091T1 (el) | Βελτιωμενο πολυπεπτιδικο μοριο διπλης ειδικοτητας | |
NZ750366A (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
MX2023006212A (es) | Anticuerpos anti inmunorreceptor de linfocitos t con dominios de motivo de inactivacion basado en tirosina de inmunorreceptor e inmunoglobulina (tigit). | |
WO2017130223A3 (en) | A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof | |
EA201992536A1 (ru) | Tcr и пептиды | |
MX2021002002A (es) | Anticuerpos anti inmunorreceptor de celulas t con dominios ig y motivo inhibidor inmunorreceptor basado en tirosina (tigit). | |
GEP20237480B (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
CU20190099A7 (es) | Dominio de unión a antígeno anti-trbc1, y receptor de antígeno quimérico, anticuerpo, acoplador biespecífico de células t y conjugado anticuerpo-fármaco que comprenden el mismo | |
NZ730933A (en) | Antigen binding molecules comprising a tnf family ligand trimer | |
MX361076B (es) | Proteínas multifunción que comprenden complejo mayor de histocompatibilidad (cmh) de clase i multivalente unido mediante disulfuro. | |
MX2018008592A (es) | Anticuerpos monoclonales humanizados inmunoestimulantes contra interleucina-2 humana, y proteinas de fusion de los mismos. | |
EA201792184A1 (ru) | Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3) | |
RU2014144143A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток | |
WO2017124001A3 (en) | T cell receptor-like antibodies specific for foxp3-derived peptides | |
PH12021550114A1 (en) | T cell-antigen coupler with various construct optimizations | |
EP4249511A3 (en) | Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof | |
RU2018140056A (ru) | Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена | |
WO2019005640A3 (en) | MULTISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING SAME | |
EA201892217A1 (ru) | Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, КОТОРЫЕ РАСПОЗНАЮТ МУТАНТНЫЕ ВАРИАНТЫ СО СДВИГОМ РАМКИ СЧИТЫВАНИЯ TGFβRII | |
MX2022000325A (es) | Anticuerpos dirigidos contra dll3 y usos de los mismos. |